Issued to LUPIN. Application meets requirements but marketing is blocked (patent/exclusivity).
Posted by FDA
September 29, 2026Application
NDA 505b1 • 220446
Product
APIXABAN
Company
LUPIN
Stage
Final Decision
Assyro regulatory brief
FreeSource facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
FDA posted a tentative approval letter for APIXABAN on 2026-09-29. This is the document posting date; consult the signed letter for the decision date. The source metadata identifies NDA 220446 as an original application. Review the exact FDA letter for the approved conditions and labeling.
Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.
Open the document workspaceFDA source document
Not for marketing yet. FDA granted tentative approval to NDA 220446 for APIXABAN, meaning the application meets approval standards but patent or exclusivity protections block final approval. The product cannot be marketed until those conditions resolve and FDA issues final approval.
NDA 220446 is the application under which FDA issued this tentative approval letter for APIXABAN to LUPIN. FDA posted the letter on September 29, 2026; the posting date is not the decision date.
The product cannot be marketed yet. Tentative approval means the application meets FDA approval standards, but patent or exclusivity protections block final approval. The sponsor typically requests final approval as the blocking date approaches, and FDA re-verifies that the approval conditions still hold before granting it.